Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice.
Onco Targets Ther. 2021 Nov 27;14:5345-5352. doi: 10.2147/OTT.S325208. eCollection 2021.
Onco Targets Ther. 2021.
PMID: 34866914
Free PMC article.
Different Pathological Complete Response Rates According to PAM50 Subtype in HER2+ Breast Cancer Patients Treated With Neoadjuvant Pertuzumab/Trastuzumab vs. Trastuzumab Plus Standard Chemotherapy: An Analysis of Real-World Data.
Díaz-Redondo T, Lavado-Valenzuela R, Jimenez B, Pascual T, Gálvez F, Falcón A, Alamo MDC, Morales C, Amerigo M, Pascual J, Sanchez-Muñoz A, González-Guerrero M, Vicioso L, Laborda A, Ortega MV, Perez L, Fernandez-Martinez A, Chic N, Jerez JM, Alvarez M, Prat A, Ribelles N, Alba E.
Díaz-Redondo T, et al. Among authors: alamo mdc.
Front Oncol. 2019 Nov 5;9:1178. doi: 10.3389/fonc.2019.01178. eCollection 2019.
Front Oncol. 2019.
PMID: 31750258
Free PMC article.
Item in Clipboard
Cite
Cite